VolitionRx well positioned as it enters Q2 after strengthening balance sheet

Cameron Reynolds, chief executive of VolitionRx Limited (NYSE AMERICAN:VNRX), tells Proactive London's Andrew Scott they're in a good place after again strengthening the balance sheet in recent weeks with a further $5 million in warrants exercised for cash.

''Total cash in hand that gives us around $21.2mln ... so it's a really good runway to get our milestones completed''.

Reynolds also updates on operational developments including their first large-scale lung cancer study being carried out in Taiwan.

Quick facts: VolitionRx

Price: $4.18

Market Cap: $171.76 m


VolitionRX hosts Capital Markets Day at the NYSE

VolitionRx (NYSE AMERICAN:VNRX) CEO Cameron Reynolds tells Proactive Investors the life sciences company has organized a Capital Markets Day to bring together shareholders, company executives and analysts at the New York Stock Exchange. The company plans to offer updates of results,...

on 9/4/19

2 min read